Delayed emesis can persist up to five days after cisplatin administration, peaking in intensity at 48 to 72 hours.
This balanced perspective on the impact of this novel could increase capacity in a service stretched to provide adequate cisplatin provision.
The first cisplatin analog to be developed was carboplatin.
The toxicity profile mirrored that of cisplatin alone with the most common toxicities being cytopenias (n 10), nausea/vomiting (n 9), and asthenia (n 5).
Clinical trials have since established cisplatin in lung, ovarian, esophageal, cervical, head and neck and germ cell cancers.
For this reason, cisplatin-induced emesis has become the human model by which antiemetic regimens are evaluated (7).
Like other traditional chemotherapeutic agents, cisplatin has untoward side-effects (nephrotoxicity, ototoxicity, and neuropathy) and clinical drug resistance does occur.
T he drugs best known t o cause anosmia are cisplatin and neuroleptic drugs.
